Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (474)	12/11/1999 2:07:00 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 3044

Most biologists are convinced that we'll need the atom jugglers for awhile longer. It'll be awhile until we turn them into lever pushers. One issue that is resolved..... MLNM is among relatively few epicenters for target generation....... and one issue that has NEVER emerged into focus, the value of combichem as a business model. >> OK, ignore PCOP, but you get the picture << Shot alert! TD.... you say that we shouldn't ignore ArQule. They didn't deliver on promises. They promised an IND by 12/98. Rachel L. at the '98 H&Q went a step further and promised two. Regardless of whether or not the leads can turn to drugs, ARQL has since turned to [admittedly lucrative] contract work, work where there is no tie to royalty. So....... ok, don't ignore them, but..... how does one invest in them and still gain exposure to biotech-like "return potential"?